Biogen Inc
-
Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trials
Ever since Medicare proposed to sharply limit coverage of the controversial Alzheimer’s drug Aduhelm, the agency has been deluged with…
Read More » -
Inside a Campaign to Get Medicare Coverage for a New Alzheimer’s Drug
In the interview, Mr. Johns echoed these explanations. Asked if association officials had communicated with Biogen since Medicare’s proposal, he…
Read More »
